{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T07:56:04Z","timestamp":1775116564660,"version":"3.50.1"},"reference-count":31,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Obesity"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>HDM1002, a small\u2010molecule agonist of glucagon\u2010like peptide\u20101 receptors, was evaluated for safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Chinese participants (18\u201360\u2009years) with BMI\u2009\u2265\u200924.0 kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      to \u2264\u200936.0\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      without diabetes were enrolled and randomized 5:1 (12 per cohort) to receive HDM1002 or placebo orally for 28\u2009days. Dose cohorts included 50\u2009mg once daily (QD); 100\u2009mg QD; 200\u2009mg QD; 100\u2009mg twice daily (BID); and 400\u2009mg QD. Primary endpoint was safety, assessed by treatment\u2010emergent adverse events (TEAEs), vital signs, physical examination, electrocardiogram, and laboratory parameters. Secondary endpoints were PK\/PD analyses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>TEAEs in 50\/100\/200\u2009mg QD, 100\u2009mg BID, and 400\u2009mg QD HDM1002 groups were 80%, 70%, 100%, 90%, and 100%, respectively, and 60% in the placebo group, all mild\/moderate. Two participants discontinued HDM1002 due to TEAEs versus none in the placebo group. Greater least squares mean reductions from baseline in body weight were among HDM1002 200\u2009mg QD (\u22126.1\u2009kg), 100\u2009mg BID (\u22124.4\u2009kg), and 400\u2009mg QD (\u22124.3\u2009kg) groups, compared with placebo (\u22121.6\u2009kg). There was no significant effect on glycemia observed with HDM1002 compared to placebo. PK were generally doseproportional.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>HDM1002 demonstrated a manageable safety\/tolerability profile.<\/jats:p>\n                    <jats:p>\n                      <jats:bold>Trial Registration:<\/jats:bold>\n                      CTR20233390\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/oby.70160","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T04:25:22Z","timestamp":1773116722000},"page":"839-850","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["<scp>HDM1002<\/scp>\n                    in Chinese Adults With Overweight\/Obesity: A Randomized, Placebo\u2010Controlled, Ascending\u2010Dose Phase 1b Study"],"prefix":"10.1002","volume":"34","author":[{"given":"Hongrong","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology, Zhongshan Hospital Fudan University  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology The Second Affiliated Hospital of Anhui Medical University  Hefei China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Zhongshan Hospital Fudan University  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenwen","family":"Tu","sequence":"additional","affiliation":[{"name":"Huadong Global R&amp;D Center, Huadong Medicine Co., Ltd  Hangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijun","family":"Shen","sequence":"additional","affiliation":[{"name":"Huadong Global R&amp;D Center, Huadong Medicine Co., Ltd  Hangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangyang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Huadong Global R&amp;D Center, Huadong Medicine Co., Ltd  Hangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Zhong","sequence":"additional","affiliation":[{"name":"Huadong Global R&amp;D Center, Huadong Medicine Co., Ltd  Hangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[{"name":"Huadong Global R&amp;D Center, Huadong Medicine Co., Ltd  Hangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junfang","family":"Xu","sequence":"additional","affiliation":[{"name":"Huadong Global R&amp;D Center, Huadong Medicine Co., Ltd  Hangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9383-5757","authenticated-orcid":false,"given":"Xiaoying","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Zhongshan Hospital Fudan University  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"World Health Organization \u201cObesity and Overweight \u201d accessed October 1 2024 https:\/\/www.who.int\/news\u2010room\/fact\u2010sheets\/detail\/obesity\u2010and\u2010overweight."},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.glohj.2022.07.007"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055643"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.161.13.1581"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcx152"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.721135"},{"key":"e_1_2_11_8_1","unstructured":"Novo Nordisk \u201cOzempic Prescribing Information \u201daccessed October 1 2024 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/209637s003lbl.pdf."},{"key":"e_1_2_11_9_1","unstructured":"Novo Nordisk \u201cVictoza Prescribing Information \u201daccessed October 1 2024 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022341lbl.pdf."},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.13483"},{"key":"e_1_2_11_11_1","unstructured":"Novo Nordisk \u201cRybelsus Prescribing Information \u201daccessed\u00a0October 1 2024 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/213051s000lbl.pdf."},{"key":"e_1_2_11_12_1","unstructured":"Novo Nordisk \u201cRybelsus Summary of Product Characteristics \u201daccessed October 1 2024 https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/rybelsus\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1900\/RDS.2014.11.202"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01185-6"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2302392"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2013.04.008"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14710"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15168"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60659-0"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411892"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/10408363.2018.1428526"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2015.07.015"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-024-00647-3"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.21358"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-2415"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP161356.ESGL"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042018821997320"}],"container-title":["Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/oby.70160","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/oby.70160","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/oby.70160","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T07:13:11Z","timestamp":1775113991000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/oby.70160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1002\/oby.70160"],"URL":"https:\/\/doi.org\/10.1002\/oby.70160","archive":["Portico"],"relation":{},"ISSN":["1930-7381","1930-739X"],"issn-type":[{"value":"1930-7381","type":"print"},{"value":"1930-739X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"2025-09-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}